This open label, single-arm and multicenter phase II study is designed to evaluate Objective Response Rate (ORR) of anti-EGFR monoclonal antibody（SCT200）in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.